News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
July, 2025
July 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Razan Mohty: Cellular therapies for acute leukemia – A Deep Dive from ASH24
Razan Mohty/X
Jan 4, 2025, 06:44

Razan Mohty: Cellular therapies for acute leukemia – A Deep Dive from ASH24

Razan Mohty, Assistant Professor at UAB Medicine, shared a post on X:

“Cellular therapies for acute leukemia: A Deep Dive from ASH24.

Feel free to add any other relevant abstract.

Razan Mohty: Cellular therapies for acute leukemia - A Deep Dive from ASH24

1. “85 Engineering Myeloid Hematopoiesis By Nonviral Chimeric Antigen Receptor Knock-in to CD33 Enhances T Cell Infiltration in the Tumor Microenvironment”

Razan Mohty: Cellular therapies for acute leukemia - A Deep Dive from ASH24

2. “369 Autologous CD33CART for Children and Adolescents/Young Adults with Relapsed/Refractory AML: Phase 1/2 Clinical Trial Correlative Biology Analyses Demonstrate Potent in Vitro, In Vivo, and Ex Vivo Anti-Leukemia Activity”

Razan Mohty: Cellular therapies for acute leukemia - A Deep Dive from ASH24

3. “371 Development of CAR T Cells Targeting U5 snRNP200 for the Treatment of Acute Myeloid and B-Lymphoid Leukemias”

Razan Mohty: Cellular therapies for acute leukemia - A Deep Dive from ASH24

4. “372 Modified Dual CLL1-CD15 and CLL1-CD16 Icar-T Cells for Mitigating Granulocytopenia Toxicities in the Treatment of Acute Myeloid Leukemia”

Razan Mohty: Cellular therapies for acute leukemia - A Deep Dive from ASH24

5. “2070 CD371-Targeted CAR T-Cells Secreting Interleukin-18 Exhibit Robust Expansion and Disease Clearance in Patients with Refractory Acute Myeloid Leukemia”

Razan Mohty: Cellular therapies for acute leukemia - A Deep Dive from ASH24

6. “2076 CD123-CAR T Cells Manufactured in the Presence of Dasatinib Induce High Grade CRS and/or IEC-HS without Improving Efficacy in Pediatric Patients with Recurrent/Refractory Leukemia”

Razan Mohty: Cellular therapies for acute leukemia - A Deep Dive from ASH24

7. “3444 Dual Inhibition of Histone and DNA Methylation in AML Enhances the Effectiveness of TCR-Based Cellular Therapy through Upregulation of Surface MHC Class I/p53 Antigen Complex”

Razan Mohty: Cellular therapies for acute leukemia - A Deep Dive from ASH24

8. “2071 Non-Engrafting CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) Achieves Remissions in Transplant-Naive Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)”

Razan Mohty: Cellular therapies for acute leukemia - A Deep Dive from ASH24

9. “4841 Phase II Clinical Trial of “Off-the-Shelf” NK Cells with Allogeneic Stem Cell Transplantation in Patients with High-Risk Myeloid Malignancies”

Razan Mohty: Cellular therapies for acute leukemia - A Deep Dive from ASH24

10. “1433 Characteristics and Outcome Determinants in Children, Adolescents and Young Adults Who Failed Tisagenlecleucel for B-Cell Acute Lymphoblastic Leukemia”

Razan Mohty: Cellular therapies for acute leukemia - A Deep Dive from ASH24

11. “4200 NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival”

Razan Mohty: Cellular therapies for acute leukemia - A Deep Dive from ASH24

12. “965 Second Infusion of CAR T-Cells in Patients with Relapsed /Refractory B-Cell Acute Lymphoblastic Leukemia: Results from a Gocart Coalition Analysis on Behalf of the PDWP, ALWP, and Ctiwp of the EBMT”

Razan Mohty: Cellular therapies for acute leukemia - A Deep Dive from ASH24

13. “2810 Allogeneic Hematopoietic Stem Cell Transplantation Following CAR T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia”

Razan Mohty: Cellular therapies for acute leukemia - A Deep Dive from ASH24

14. “4845 Risk Factors Associated with Sub-Optimal Outcomes Following Obecabtagene autoleucel (obe-cel) for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): What We Have Learned from the FELIX Trial”

Razan Mohty: Cellular therapies for acute leukemia - A Deep Dive from ASH24

15. “3458 Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) in the Open-Label, Multi-Center, Global, Single-Arm, Phase Ib/II FELIX Study: The Impact of Bridging Therapies on CAR T-Cell Expansion and Persistence”

Razan Mohty: Cellular therapies for acute leukemia - A Deep Dive from ASH24

16. “963 Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): Deep Molecular Remission May Predict Better Outcomes”

Razan Mohty: Cellular therapies for acute leukemia - A Deep Dive from ASH24

17. “2078 Initial Results of a First-in-Human, Phase I Study Point-of-Care Manufacturing of Trispecific CAR-T Cells Targeting CD19/20/22 in B-Cell Malignancies”

Razan Mohty: Cellular therapies for acute leukemia - A Deep Dive from ASH24

18. “4197 Chemotherapy-Free Induction with Venetoclax and Azacitidine, Followed By Tandem CD19/CD22 CAR-T Cell Therapy As First-Line Treatment in Newly Diagnosed High-Risk Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Prospective, Single-Center, Single-Arm, Phase 2 Trial”

Razan Mohty: Cellular therapies for acute leukemia - A Deep Dive from ASH24

19. “3450 WU-CART-007 (WT-7), an Allogeneic CAR T-Cell Targeting CD7 in Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LBL): Phase 2 Results”

Razan Mohty: Cellular therapies for acute leukemia - A Deep Dive from ASH24

20. “4830 CD7.Pebl-CART for Patients with Relapsed/Refractory (r/r) T-Cell Acute Lymphoblastic Leukemia (T-ALL)”

Razan Mohty: Cellular therapies for acute leukemia - A Deep Dive from ASH24

21. “4838 BEAM-201 for the Treatment of Relapsed and/or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL): Initial Data from the Phase (Ph) 1/2 Dose-Exploration, Dose-Expansion, Safety, and Efficacy Study of Multiplex Base-Edited Allogeneic Anti‑CD7 CAR-T-Cells”

Razan Mohty: Cellular therapies for acute leukemia - A Deep Dive from ASH24

More posts featuring Razan Mohty.

acute leukemia Acute Myeloid Leukaemia AML ASH24 cancer Cellular Therapy OncoDaily Oncology Razan Mohty T-ALL T-cell acute lymphoblastic leukemia
Special Coverage
Insight
Jul 3, 2025, 17:51
Maximilian Merz: How to Train Your Virtual Twin with 10 Million Euros
Blog
Jul 3, 2025, 17:40
Susanna Fletcher Greer: Striving to Support the Whole Person Behind the Science at the V Foundation
Opinion
Jul 3, 2025, 17:35
Andrew M Wardley: The Essential Role of a Cancer Plan in Shaping the Future of Cancer Care in the UK
Career
Jul 3, 2025, 17:22
George Yaghmour: Honored to Be Named The Leukemia and Lymphoma Society’s 2025 All-Star Top Fundraiser with 255,826 Dollars
Blog
Jul 3, 2025, 17:10
Oliver Bogler: Why I am Learning a New Way to Support Scientists
Blog
Jul 3, 2025, 17:01
Annalisa Saetta: Palliative Care Clerkship Increased Students’ Knowledge and Appreciation for a Holistic Approach
Blog
Jul 3, 2025, 16:46
Priscilla Chan: Accelerating Imaging Science so Researchers Can See Biology More Clearly
Insight
Jul 3, 2025, 16:42
Highlights From ESMO Gastrointestinal Cancers Congress 2025 by Arndt Vogel
Career
Jul 3, 2025, 16:19
David Weinstock Has Been Appointed Head of the Oncology Disease Translational Area in pRED at Roche
Career
Jul 3, 2025, 16:10
Bruno Vialli Has Been Appointed LATAM Procurement Manager for Media, Comms and Events at Sanofi
Insight
Jul 3, 2025, 16:01
Paolo Tarantino: First Positive Phase 3 Trial for a Bispecific ADC
Insight
Jul 3, 2025, 15:48
ASMIRT shares updates on advocacy, research, and student support in Australia - ESTRO